/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
May 18, 2022 at 11:06 AM
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)
March 10, 2022 at 12:14 PM
An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, multiple sclerosis, inflammatory, MS, major depressive disorder (MDD), myelin degradation, bipilar disorder
November 30, 2021 at 6:22 PM
An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, fibrotic, multiple sclerosis, Huntingtons Disease, cannabigerol, SSc, inflammatory, systemic sclerosis, MS, Parkinsons Disease, cannabinoids, cannabidiol
November 9, 2015 at 5:38 PM
In just six months, drug companies have spent $221 billion buying each other, with a lot of recent mergers being between biotech firms. So what is driving the deals? Business television show Arise Xchange sits down with Jeff Kraws, Cofounder and CEO of Crystal Research Associates, to discuss.
Runtime: 3:38 minutes
January 24, 2011 at 10:01 AM
We at Crystal are looking forward to an exciting week as we begin releasing new research in our revamped Coverage Library. This morning, we published a business update on innovative biopharmaceutical company, Peregrine Pharmaceuticals, Inc. (PPHM-NASDAQ).
Topics: New Research, biopharmaceuticals
October 28, 2010 at 10:40 AM
Today, Bioniche Life Sciences Inc. (BNC-TSX), a research-based, technology-driven Canadian biopharmaceutical company, announced that it was named among the Top 50 Best Small and Medium Employers in Canada. Ranked 14th, Bioniche believes that its employees, who are also shareholders, are among the Company’s greatest assets. The rankings were determined using employee opinion surveys, an assessment of organization practices, and perspectives from the leadership team. More than 160 companies across Canada registered to participate in the study, which was conducted by the Queen’s Centre for Business Venturing, the Queen’s University School of Business, and Aon Hewitt.
Topics: Newsworthy Events, Bioniche, biopharmaceuticals
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS